Curriculum · Gynecology / Women's Health / Infertility / Perinatal Care / Birth Spacing
Contraception in sickle cell disease
What it is
Contraception for a woman with SCD is chosen from the same four groups set out for any woman: the condom, diaphragm and cervical cap; the combined OCP; progesterone only methods; and intrauterine devices. SCD itself appears twice in that table, and both times the choice moves away from estrogen. SCD is named among the relative contraindications to the combined OCP, alongside DM, HTN, dyslipidemia, anticonvulsant use and gallbladder disease. Acute SCD crisis is named among the non-contraceptive uses of DMPA, the IM agent Depo Provera, also written as depot medroxyprogesterone acetate.
How it is treated
Progesterone only contraception comes in two types: the mini pills, taken daily, and the IM agents (Depo Provera, DMPA), given once every 3 months. Their stated advantages are that there is no DVT risk because there is no estrogen, that they are used when estrogen is contraindicated, and that they are safe in breast feed and improve milk quality. Ovulation is immediately reversible with the POP, so menses return. The combined OCP is given as 21 active pills with 7 placebo; it suppresses LH and FSH to give anovulation, thickens the cervical mucosa to inhibit migration and thins the endometrial lining to inhibit implantation, and its failure is 0.1%. The two are set against each other on absorption as well: the combined pill depends on gut flora, that is bacteria, for its absorption, so it is affected by Abs, and it has a low effect if taken with an anticonvulsant or griseofulvin, while the progesterone only methods do not depend on gut flora and are not affected by ABS. Intrauterine devices alter tubal motility. The copper IUD (paragard) lasts 10-12 yrs with 0.8% failure and acts by a fall in sperm motility and acrosomal enzyme action and by endometrial inflammation, while the hormonal IUD (Mirena) contains progesterone, thickens the cervical mucus, thins the endometrium, lasts 7 yrs with 0.1% failure and improves menorrhagia. The condom and diaphragm reduce STD and PID, but the cap does so only if it contains spermicide. After giving birth, contraception is required after day 21, since the earliest date of ovulation in a non-breastfeeding woman is thought to be day 28 postpartum and sperm can survive for up to 7 days. The progestogen only pill can be started at any time postpartum, and after day 21 additional contraception is used for the first 2 days; a small amount of progestogen enters breast milk but this is not harmful to the infant. The combined pill may be started from day 21, which gives immediate contraception, and after day 21 additional contraception is used for the first 7 days. The Mirena intrauterine system and the copper IUD can be used from 4 weeks postpartum, and the copper device should not be inserted before day 28 postpartum because of the increased risk of uterine perforation. The progestogen only implant can be inserted at any time, and contraception is not required before day 21. Lactational amenorrhoea is an effective contraceptive in itself, 98% effective, provided the woman is fully breast-feeding with no supplementary feeds, is amenorrhoeic, and is under 6 months post-partum.
What can go wrong
The progesterone only methods carry a mini pill failure of 8% and a Provera failure of 3%, irregular bleed at the beginning, weight gain, breast tenderness and mood swing. Return of ovulation is late after DMPA, around 10 months, and DMPA gives a low HDL. The POP has a low effect with anticonvulsants. Breast cancer in the last 5 yrs is the absolute contraindication to progesterone only methods. For the combined OCP, SCD sits on the relative and not the absolute list; the absolute list is pregnancy, undiagnosed vaginal bleed, CAD, HTN above 160/100, valvular disease, stroke or MI, DVT, PE, migraine with aura, current breast, endometrial or melanoma malignancy, liver tumor, viral hepatitis or abnormal LFT, breast feed under 6 wks, major surgery with prolonged immobilization, and smoking over 15 a day above age 35. Intrauterine devices bring a raised PID risk in the 1st 20 yrs, uterine perforation, fainting with insertion, expulsion and unexpected pregnancy if placement is poor; copper gives more bleed and dysmenorrhea while Mirena causes amenorrhea. They carry contraindications of their own, and those are what decide for a woman in whom estrogen is only relatively contraindicated, since the intrauterine route is what is left open to her. The absolute contraindications are pregnancy, undiagnosed vaginal bleed, acute cervicitis, endometritis or salpingitis, a past salpingitis, and suspected gynecological malignancy. The relative ones are nulliparity, a desire for future pregnancy, a past ectopic pregnancy, a past STD, multiple sexual partners, an abnormal uterine cavity, moderate to severe dysmenorrhea, chronic menometrorrhagia and IDA. The eligibility criteria put numbers on the same lists. For the combined pill, use at less than 6 weeks postpartum while breastfeeding is an unacceptable risk, UKMEC 4, and between 6 weeks and 6 months postpartum it is UKMEC 2; the combined pill may also reduce breast milk production in lactating mothers. For the progestogen methods, UKMEC 3 covers ischaemic heart disease or stroke for continuation, unexplained or suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis and liver cancer, while UKMEC 4, current breast cancer, is the unacceptable risk. With enzyme-inducing drugs the advice is to switch to a method unaffected by them, or to use additional contraception until 28 days after stopping the treatment. Depo-Provera carries a delay in the return of fertility of up to 1 year in women over 40, and its use is associated with a small loss in bone mineral density which is usually recovered after discontinuation.